Immunomedics, Inc. (NASDAQ:IMMU) insider Avoro Capital Advisors Llc acquired 750,000 shares of the company’s stock in a transaction dated Wednesday, May 15th. The stock was bought at an average cost of $15.11 per share, for a total transaction of $11,332,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Avoro Capital Advisors Llc also recently made the following trade(s):

  • On Monday, May 13th, Avoro Capital Advisors Llc acquired 500,000 shares of Immunomedics stock. The stock was bought at an average cost of $15.07 per share, for a total transaction of $7,535,000.00.

NASDAQ:IMMU traded down $0.48 during mid-day trading on Wednesday, reaching $14.93. 2,055,043 shares of the company’s stock were exchanged, compared to its average volume of 3,111,805. Immunomedics, Inc. has a one year low of $11.55 and a one year high of $27.33. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -14.50 and a beta of 1.97. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.89 and a current ratio of 7.89.

Immunomedics (NASDAQ:IMMU) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). During the same period last year, the company earned ($0.21) EPS. Sell-side analysts anticipate that Immunomedics, Inc. will post -1.39 EPS for the current year.

IMMU has been the topic of a number of recent research reports. BidaskClub raised shares of Immunomedics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 15th. Wells Fargo & Co lowered shares of Immunomedics from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $44.00 to $18.00 in a research report on Friday, January 18th. Cowen reaffirmed a “buy” rating and set a $30.00 price target on shares of Immunomedics in a research report on Friday, January 18th. Jefferies Financial Group set a $21.00 price target on shares of Immunomedics and gave the stock a “buy” rating in a research report on Friday, January 18th. Finally, Piper Jaffray Companies lowered their price target on shares of Immunomedics to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $28.45.

A number of institutional investors have recently made changes to their positions in IMMU. FMR LLC grew its stake in Immunomedics by 48.2% during the fourth quarter. FMR LLC now owns 8,235,480 shares of the biopharmaceutical company’s stock worth $117,519,000 after buying an additional 2,677,246 shares in the last quarter. TimesSquare Capital Management LLC acquired a new stake in Immunomedics during the first quarter worth about $44,379,000. Fiera Capital Corp acquired a new stake in Immunomedics during the first quarter worth about $39,804,000. Norges Bank acquired a new stake in Immunomedics during the fourth quarter worth about $16,141,000. Finally, Frontier Capital Management Co. LLC acquired a new stake in Immunomedics during the first quarter worth about $20,859,000. Hedge funds and other institutional investors own 86.11% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by Marea Informative and is the property of of Marea Informative. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.mareainformativa.com/news/2019/05/15/insider-buying-immunomedics-inc-immu-insider-purchases-750000-shares-of-stock.html.

About Immunomedics

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Read More: What is a resistance level?

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.